
  
    
      
        Background_NNP
        Over_IN the_DT last_JJ decade_NN ,_, RNA_NNP interference_NN (_( RNAi_NNP )_) ,_, mediated_JJ
        by_IN short_JJ interfering_VBG double-stranded_JJ RNA_NNP molecules_NNS (_( siRNA_NN
        or_CC dsRNA_NN )_) ,_, has_VBZ been_VBN gradually_RB recognized_VBN as_IN a_DT major_JJ
        mechanism_NN of_IN post-transcriptional_JJ gene_NN silencing_VBG (_( PTGS_NNP )_) in_IN
        species_NNS as_RB diverse_JJ as_IN plants_NNS ,_, 
        Drosophila_NNP ,_, and_CC 
        C_NNP ._. elegans_NNS [_NN 1_CD ]_NN ._. Recently_RB ,_,
        21_CD -_: nucleotide_NN long_JJ dsRNA_NN molecules_NNS corresponding_JJ to_TO
        specific_JJ mRNA_NN sequences_NNS ,_, when_WRB introduced_VBN into_IN mammalian_JJ
        cells_NNS in_IN culture_NN ,_, have_VBP been_VBN shown_VBN to_TO be_VB highly_RB effective_JJ in_IN
        degrading_JJ the_DT cognate_NN mRNAs_NNS and_CC thus_RB abrogating_VBG the_DT
        expression_NN of_IN the_DT corresponding_JJ proteins_NNS [_NN 2_CD ]_NN ._. Although_IN
        the_DT exact_JJ mechanism_NN of_IN PTGS_NNP is_VBZ currently_RB unknown_JJ and_CC is_VBZ an_DT
        area_NN of_IN intense_JJ research_NN ,_, the_DT successful_JJ use_NN of_IN this_DT
        phenomenon_NN in_IN cultured_JJ mammalian_JJ cells_NNS has_VBZ raised_VBN the_DT
        exciting_JJ prospect_NN that_IN it_PRP can_MD be_VB used_VBN as_IN a_DT simple_JJ strategy_NN
        for_IN phenotypic_JJ ablation_NN of_IN mammalian_JJ gene_NN function_NN 
        ex_FW vivo_NN without_IN the_DT time-consuming_JJ
        and_CC expensive_JJ construction_NN of_IN transgenic_JJ animals_NNS ._.
        So_RB far_RB ,_, the_DT genes_NNS targeted_VBN for_IN siRNA-mediated_JJ PTGS_NNP have_VBP
        been_VBN cellular_JJ in_IN origin_NN and_CC thus_RB ,_, the_DT mRNAs_NNS were_VBD
        transcribed_JJ in_IN the_DT nucleus_NN by_IN cellular_JJ DNA-dependent_NNP RNA_NNP
        polymerase_NN ._. In_IN contrast_NN ,_, the_DT vast_JJ majority_NN of_IN RNA_NNP genomes_NNS
        are_VBP transcribed_JJ exclusively_RB in_IN the_DT cytoplasm_NN ._. For_IN example_NN ,_,
        transcription_NN of_IN RNA_NNP viral_JJ genomes_NNS ,_, with_IN the_DT exception_NN of_IN
        retroviral_NN RNA_NNP ,_, is_VBZ catalyzed_JJ by_IN a_DT virally_RB encoded_JJ
        RNA-dependent_NNP RNA_NNP polymerase_NN (_( RdRP_NNP )_) [_NN 3_CD ]_NN ._. It_PRP remains_VBZ
        untested_JJ whether_IN the_DT siRNA-mediated_JJ PTGS_NNP will_MD work_VB on_IN mRNAs_NNS
        that_WDT never_RB went_VBD through_IN the_DT nucleus_NN ._. Interestingly_RB ,_, because_IN
        of_IN the_DT potency_NN of_IN siRNA_NN in_IN some_DT organisms_NNS ,_, it_PRP has_VBZ been_VBN
        proposed_VBN that_IN they_PRP may_MD be_VB replicated_VBN by_IN a_DT cellular_JJ RdRP_NNP
        activity_NN ,_, although_IN this_DT has_VBZ been_VBN debated_VBN [_NN 4_CD ]_NN ._.
        Furthermore_RB ,_, since_IN dsRNA_NN is_VBZ known_VBN to_TO be_VB a_DT potent_JJ inducer_NN of_IN
        the_DT interferon_NN pathway_NN [_NN 5_CD 6_CD ]_NN ,_, it_PRP is_VBZ important_JJ to_TO know_VB
        whether_IN this_DT also_RB occurs_VBZ in_IN cells_NNS in_IN which_WDT antisense_NN dsRNA_NN
        has_VBZ been_VBN introduced_VBN ._.
        To_TO answer_VB these_DT questions_NNS ,_, we_PRP have_VBP used_VBN a_DT nonsegmented_JJ
        negative-strand_JJ RNA_NNP (_( NNR_NNP )_) virus_NN as_IN a_DT test_NN target_NN for_IN
        RNA-mediated_NNP inhibition_NN ._. We_PRP reasoned_VBD that_IN ,_, if_IN successful_JJ ,_,
        our_PRP$ studies_NNS would_MD additionally_RB contribute_VB a_DT reliable_JJ and_CC
        simple_JJ technology_NN for_IN specific_JJ gene_NN silencing_VBG in_IN
        cytoplasmic_JJ RNA_NNP viruses_NNS ._. Traditionally_RB ,_, structure-function_JJ
        analyses_NNS of_IN RNA_NNP genomes_NNS ,_, including_VBG those_DT of_IN RNA_NNP viruses_NNS ,_,
        have_VBP relied_VBN on_IN spontaneous_JJ mutants_NNS found_VBD in_IN natural_JJ
        isolates_VBZ or_CC chemically_RB mutagenized_JJ stocks_NNS [_NN 7_CD ]_NN ._. Mutations_NNP
        in_IN either_DT case_NN are_VBP essentially_RB unpredictable_JJ and_CC must_MD be_VB
        mapped_VBN by_IN elaborate_VB techniques_NNS such_JJ as_IN classical_JJ
        complementation_NN analyses_NNS or_CC direct_JJ sequencing_VBG of_IN the_DT
        genome_NN ._. Since_IN conventional_JJ site-directed_JJ mutagenesis_NNS
        requires_VBZ a_DT DNA_NNP template_NN ,_, direct_JJ mutational_NN analysis_NN of_IN
        selected_VBN RNA_NNP genes_NNS is_VBZ not_RB an_DT option_NN ._. These_DT obstacles_NNS have_VBP
        been_VBN largely_RB circumvented_JJ by_IN the_DT use_NN of_IN cloned_VBN viral_JJ cDNA_NN
        that_WDT is_VBZ then_RB altered_VBN by_IN standard_JJ DNA-based_NNP site-directed_JJ
        mutagenesis_NNS procedures_NNS [_NN 8_CD 9_CD ]_NN ._. Originally_RB designed_VBN for_IN
        influenza_NN virus_NN minigenomes_NNS [_NN 10_CD ]_NN ,_, such_JJ cDNA-based_JJ
        "_'' reverse_VB genetics_NNS "_'' strategy_NN has_VBZ been_VBN adopted_VBN in_IN a_DT large_JJ
        number_NN of_IN NNR_NNP viruses_NNS ,_, including_VBG vesicular_NN stomatitis_NNS virus_NN
        (_( VSV_NNP )_) ,_, respiratory_JJ syncytial_NN virus_NN (_( RSV_NNP )_) ,_, and_CC measles_NNS ,_, to_TO
        name_VB a_DT few_JJ [_NN 11_CD 12_CD 13_CD 14_CD ]_NN ._. Recently_RB ,_, extension_NN of_IN this_DT
        approach_NN has_VBZ resulted_VBN in_IN the_DT cloning_VBG of_IN full-length_JJ viral_JJ
        cDNA_NN capable_JJ of_IN producing_VBG infectious_JJ recombinant_JJ virus_NN
        particles_NNS upon_IN transcription_NN ._.
        Despite_IN its_PRP$ revolutionary_JJ effect_NN on_IN RNA_NNP viral_JJ reverse_NN
        genetics_NNS ,_, however_RB ,_, the_DT cDNA-based_JJ strategy_NN is_VBZ not_RB without_IN
        limitations_NNS ._. First_LS ,_, as_IN implied_VBN above_IN ,_, cloning_VBG and_CC
        recombinant_JJ expression_NN of_IN the_DT viral_JJ genomic_JJ RNA_NNP and_CC all_PDT the_DT
        viral_JJ proteins_NNS in_IN the_DT right_JJ proportion_NN constitute_VBP a_DT long_JJ
        and_CC arduous_JJ task_NN ,_, daunting_VBG to_TO an_DT average_JJ laboratory_NN ._. The_DT
        problem_NN is_VBZ particularly_RB acute_JJ for_IN NNR_NNP viruses_NNS ,_, which_WDT have_VBP
        large_JJ RNA_NNP genomes_NNS [_NN 8_CD 9_CD ]_NN ._. The_DT 10_CD -_: 15_CD kb_NN long_JJ RNA_NNP genomes_NNS
        of_IN these_DT viruses_NNS require_VBP specific_JJ sequences_NNS at_IN the_DT 5_CD '_POS and_CC
        3_CD '_POS termini_NN for_IN transcription_NN and_CC replication_NN ,_, and_CC must_MD be_VB
        properly_RB encapsidated_JJ by_IN the_DT nucleocapsid_NN protein_NN (_( N_NNP )_) in_IN
        order_NN to_TO be_VB recognized_VBN by_IN the_DT viral_JJ RdRP_NNP [_NN 15_CD 16_CD ]_NN ._. Thus_RB ,_,
        any_DT recombinant_JJ technology_NN must_MD be_VB able_JJ to_TO faithfully_RB
        reproduce_VB these_DT features_NNS of_IN the_DT genome_NN ._. Moreover_RB ,_, the_DT
        functional_JJ viral_JJ RdRP_NNP ,_, as_IN detailed_JJ later_RB for_IN RSV_NNP ,_, is_VBZ a_DT
        complex_JJ holoenzyme_NN composed_VBN of_IN viral_JJ as_IN well_RB as_IN cellular_JJ
        proteins_NNS [_NN 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD 23_CD ]_NN ._. Second_JJ ,_, many_JJ NNR_NNP viral_JJ
        genomes_NNS and_CC proteins_NNS are_VBP currently_RB expressed_VBN from_IN
        vaccinia-based_JJ cDNA_NN clones_NNS ,_, which_WDT generally_RB requires_VBZ
        superinfection_NN by_IN vaccinia_NN virus_NN [_NN 22_CD 23_CD ]_NN ._. Unfortunately_RB ,_,
        vaccinia_NN virus_NN itself_PRP is_VBZ a_DT major_JJ modulator_NN of_IN cellular_JJ
        signaling_VBG ,_, including_VBG MAP_NNP kinase_NN pathways_NNS and_CC the_DT actin_NN
        cytoskeleton_NN [_NN 24_CD 25_CD 26_CD ]_NN ._. It_PRP is_VBZ ,_, therefore_RB ,_, virtually_RB
        impossible_JJ to_TO study_VB the_DT interaction_NN between_IN cellular_JJ
        signaling_VBG pathways_NNS and_CC NNR_NNP viruses_NNS in_IN cells_NNS that_WDT are_VBP also_RB
        superinfected_JJ by_IN vaccinia_NN virus_NN [_NN 24_CD 25_CD 26_CD ]_NN ._. Third_NNP ,_,
        mutations_NNS in_IN the_DT recombinant_JJ DNA_NNP are_VBP "_'' permanent_JJ "_'' ,_, and_CC thus_RB ,_,
        the_DT mutational_NN phenotype_NN cannot_NN be_VB switched_VBN on_IN at_IN
        pre-determined_JJ time_NN points_NNS in_IN infection_NN ._. For_IN example_NN ,_, if_IN a_DT
        viral_JJ gene_NN product_NN has_VBZ essential_JJ roles_NNS both_DT early_JJ and_CC late_RB
        in_IN infection_NN ,_, its_PRP$ mutational_NN inactivation_NN will_MD fail_VB to_TO
        reveal_VB the_DT late_JJ function_NN ,_, since_IN the_DT mutant_JJ virus_NN will_MD never_RB
        proceed_VB beyond_IN the_DT early_JJ stage_NN ._.
        A_DT member_NN of_IN the_DT 
        Paramyxoviridae_NNP family_NN ,_, RSV_NNP is_VBZ a_DT
        major_JJ causative_JJ agent_NN of_IN childhood_NN respiratory_JJ disease_NN and_CC
        asthma_NN [_NN 27_CD ]_NN ._. Pediatric_NNP RSV_NNP disease_NN claims_NNS about_RB a_DT
        million_CD lives_NNS annually_RB ,_, and_CC no_DT reliable_JJ antiviral_JJ or_CC
        vaccine_NN currently_RB exists_VBZ [_NN 27_CD 28_CD ]_NN ._. A_DT need_VBP to_TO understand_VB
        the_DT molecular_JJ genetics_NNS of_IN the_DT virus_NN and_CC the_DT function_NN of_IN the_DT
        various_JJ gene_NN products_NNS has_VBZ thus_RB been_VBN appreciated_VBN ._. Since_IN our_PRP$
        laboratory_NN is_VBZ interested_VBN in_IN deciphering_VBG the_DT temporal_JJ
        signaling_VBG pathways_NNS in_IN host-_NN RSV_NNP interaction_NN and_CC the_DT role_NN of_IN
        RSV_NNP gene_NN products_NNS in_IN the_DT process_NN ,_, we_PRP have_VBP sought_VBN potential_JJ
        alternatives_NNS to_TO the_DT cDNA-based_JJ approach_NN that_WDT might_MD allow_VB us_PRP
        to_TO study_VB the_DT effect_NN of_IN functional_JJ loss_NN of_IN a_DT specific_JJ RSV_NNP
        gene_NN product_NN during_IN the_DT course_NN of_IN a_DT standard_JJ virus_NN
        infection_NN in_IN cell_NN culture_NN ._. Using_VBG two_CD different_JJ RSV_NNP gene_NN
        mRNAs_NNS as_IN targets_NNS ,_, and_CC another_DT NNR_NNP virus_NN (_( VSV_NNP )_) as_RB well_RB as_IN
        cellular_JJ mRNAs_NNS as_IN controls_NNS ,_, we_PRP show_VBP that_IN synthetic_JJ dsRNA_NN
        molecules_NNS are_VBP highly_RB efficient_JJ and_CC specific_JJ silencers_NNS of_IN
        cytoplasmic_JJ RNA_NNP viral_JJ gene_NN expression_NN ._. We_PRP also_RB provide_VBP the_DT
        first_JJ direct_JJ evidence_NN that_IN the_DT 21_CD -_: nt_RB long_JJ dsRNAs_NNS do_VBP not_RB
        activate_VBP a_DT general_JJ interferon_NN response_NN ._. Our_PRP$ results_NNS thus_RB
        offer_VBP a_DT mechanism_NN of_IN specific_JJ and_CC direct_JJ ablation_NN of_IN
        RNA-based_NNP gene_NN expression_NN and_CC a_DT quicker_JJR and_CC simpler_JJR
        alternative_NN to_TO cDNA-based_JJ reverse_NN genetics_NNS of_IN RNA_NNP
        viruses_NNS ._.
      
      
        Results_NNS
        
          Ablation_NNP of_IN viral_JJ gene_NN expression_NN by_IN dsRNA_NN against_IN
          RSV_NNP P_NN mRNA_NN
          The_DT RNA_NNP genome_NN of_IN RSV_NNP is_VBZ about_IN 15_CD kb_NN long_JJ and_CC contains_VBZ
          11_CD documented_VBN protein-coding_JJ genes_NNS [_NN 13_CD ]_NN ._. Three_CD viral_JJ
          proteins_NNS are_VBP minimally_RB required_VBN to_TO reconstitute_NN the_DT
          functional_JJ transcription_NN complex_NN of_IN NNR_NNP viruses_NNS [_NN 3_CD ]_NN :_:
          the_DT nucleocapsid_NN protein_NN (_( N_NNP )_) that_WDT wraps_VBZ the_DT
          negative-strand_JJ genome_NN RNA_NNP and_CC its_PRP$ full-length_JJ
          complement_VB ,_, the_DT positive-strand_JJ antigenome_NN RNA_NNP ,_, thus_RB
          converting_VBG them_PRP into_IN highly_RB nuclease-resistant_JJ ,_,
          chromatin-like_JJ templates_NNS ;_: the_DT large_JJ protein_NN (_( L_NNP )_) ,_, which_WDT is_VBZ
          the_DT major_JJ subunit_NN of_IN the_DT RdRP_NNP ;_: and_CC the_DT phosphoprotein_NN
          (_( P_NN )_) ,_, which_WDT is_VBZ the_DT smaller_JJR subunit_NN of_IN RdRP_NNP and_CC an_DT
          essential_JJ transcription_NN factor_NN of_IN L_NNP [_NN 19_CD 20_CD 21_CD 22_CD ]_NN ._. In_IN
          RSV_NNP ,_, optimal_NN transcription_NN ,_, although_IN not_RB replication_NN ,_,
          additionally_RB requires_VBZ the_DT transcription_NN antitermination_NN
          protein_NN M_NNP 2_CD -_: 1_CD [_NN 13_CD ]_NN ._. In_IN addition_NN ,_, cellular_JJ actin_NN ,_, and_CC to_TO
          a_DT lesser_JJR extent_NN ,_, profilin_NN ,_, are_VBP also_RB required_VBN for_IN viral_JJ
          transcription_NN [_NN 17_CD 18_CD ]_NN ._.
          The_DT overall_JJ steps_NNS of_IN a_DT NNR_NNP viral_JJ macromolecular_NN
          synthesis_NN in_IN the_DT infected_JJ cell_NN are_VBP relevant_JJ for_IN this_DT
          paper_NN ,_, and_CC are_VBP briefly_RB described_VBN here_RB [_NN 3_CD ]_NN ._. The_DT L_NNP
          protein_NN is_VBZ believed_VBN to_TO encode_NN the_DT basic_JJ RNA_NNP
          polymerization_NN function_NN ,_, and_CC binds_NNS to_TO the_DT viral_JJ promoter_NN
          at_IN the_DT 3_CD '_POS end_NN of_IN the_DT genomic_JJ RNA_NNP to_TO initiate_VB
          transcription_NN ._. However_RB ,_, the_DT P_NN protein_NN is_VBZ essential_JJ for_IN
          the_DT RdRP_NNP holoenzyme_NN to_TO exit_VB the_DT promoter_NN and_CC to_TO form_VB a_DT
          closed_VBD complex_JJ that_WDT is_VBZ capable_JJ of_IN sustained_VBN elongation_NN [_NN
          20_CD ]_NN ._. The_DT preformed_JJ RdRP_NNP brought_VBD in_IN by_IN the_DT infecting_VBG
          viral_JJ nucleocapsids_NNS catalyzes_NNS the_DT first_JJ rounds_NNS of_IN
          transcription_NN ,_, known_VBN as_IN primary_JJ transcription_NN ._. In_IN its_PRP$
          "_'' transcription_NN mode_NN "_'' ,_, the_DT viral_JJ RdRP_NNP starts_VBZ and_CC stops_VBZ at_IN
          the_DT beginning_NN and_CC end_NN ,_, respectively_RB ,_, of_IN each_DT viral_JJ gene_NN ,_,
          and_CC this_DT results_NNS in_IN the_DT synthesis_NN of_IN individual_JJ gene_NN
          mRNAs_NNS ._. Unlike_IN the_DT full-length_JJ genomic_JJ and_CC antigenomic_JJ
          RNA_NNP ,_, the_DT mRNAs_NNS are_VBP 5_CD '_POS -_: capped_VBD ,_, 3_CD '_POS -_: polyadenylated_JJ ,_, and_CC do_VBP
          not_RB bind_NN N_NNP protein_NN ._. Translation_NN of_IN these_DT mRNAs_NNS results_NNS in_IN
          
          de_IN novo_NN synthesis_NN of_IN viral_JJ
          proteins_NNS ._. The_DT availability_NN of_IN large_JJ quantities_NNS of_IN N_NNP
          protein_NN then_RB allows_VBZ encapsidation_NN of_IN nascent_NN leader_NN RNA_NNP
          by_IN N_NNP ._. This_DT leads_VBZ to_TO the_DT switching_NN of_IN the_DT RdRP_NNP to_TO the_DT
          "_'' replication_NN mode_NN "_'' ,_, resulting_VBG in_IN the_DT synthesis_NN of_IN
          full-length_JJ ,_, encapsidated_JJ anti-genomic_JJ RNA_NNP ,_, which_WDT is_VBZ in_IN
          turn_NN replicated_VBN into_IN more_RBR genomic_JJ RNA_NNP [_NN 15_CD ]_NN ._. Thus_RB ,_, the_DT
          very_JJ requirement_NN of_IN N_NNP for_IN replication_NN ensures_VBZ that_IN all_DT
          full-length_JJ genomic_JJ and_CC antigenomic_JJ RNA_NNP are_VBP wrapped_VBN with_IN
          N_NNP protein_NN ,_, i_NNP ._. e_SYM ._. ,_, encapsidated_JJ [_NN 15_CD ]_NN ._. The_DT new_JJ pool_NN of_IN
          replicated_VBN genomic_JJ RNA_NNP serves_VBZ as_IN templates_NNS for_IN secondary_JJ
          transcription_NN ._. It_PRP should_MD be_VB obvious_JJ from_IN the_DT foregoing_VBG
          that_IN the_DT 
          de_IN novo_NN macromolecular_NN synthesis_NN
          accounts_NNS for_IN the_DT major_JJ burst_NN of_IN viral_JJ protein_NN and_CC RNA_NNP in_IN
          the_DT infected_JJ cell_NN ._. Specifically_RB ,_, if_IN the_DT 
          de_IN novo_NN synthesis_NN of_IN the_DT essential_JJ
          subunits_NNS of_IN viral_JJ RdRP_NNP -_: such_JJ as_IN L_NNP or_CC P_NN -_: is_VBZ inhibited_VBD ,_,
          it_PRP will_MD abolish_VB the_DT bulk_NN of_IN viral_JJ transcription_NN and_CC
          replication_NN ,_, and_CC hence_RB ,_, viral_JJ translation_NN [_NN 3_CD ]_NN ._.
          To_TO test_VB the_DT effectiveness_NN of_IN the_DT anti-_NN P_NN dsRNA_NN ,_, we_PRP
          transfected_JJ the_DT dsRNA_NN into_IN A_DT 549_CD cells_NNS ,_, and_CC infected_VBD the_DT
          cells_NNS with_IN RSV_NNP ._. Subsequently_RB ,_, the_DT amount_NN of_IN intracellular_NN
          P_NN protein_NN was_VBD directly_RB monitored_VBN by_IN immunoblot_NN analysis_NN
          using_VBG anti-_NN P_NN antibody_NN ._. Results_NNS presented_VBN in_IN Fig_NNP ._. 1_LS show_NN a_DT
          nearly_RB 90_CD %_NN reduction_NN of_IN P_NN protein_NN using_VBG as_RB little_JJ as_IN 10_CD
          nM_NN dsRNA_NN ._. Although_IN we_PRP have_VBP not_RB tested_VBN lower_JJR amounts_NNS of_IN
          dsRNA_NN for_IN P_NN ,_, the_DT severe_JJ loss_NN of_IN P_NN protein_NN at_IN 10_CD nM_NN dsRNA_NN
          and_CC only_RB a_DT slightly_RB greater_JJR loss_NN with_IN higher_JJR dsRNA_NN
          concentrations_NNS (_( Fig_NNP ._. 1_LS )_) suggest_VBP that_IN it_PRP may_MD be_VB possible_JJ
          to_TO cause_VB substantial_JJ ablation_NN of_IN P_NN protein_NN at_IN dsRNA_NN
          concentrations_NNS even_RB below_IN 10_CD nM_NN ._.
          The_DT phenotypic_JJ effect_NN of_IN loss_NN of_IN P_NN was_VBD further_RBR
          examined_VBN by_IN measuring_VBG progeny_NN viral_JJ titer_NN ,_, overall_JJ viral_JJ
          protein_NN synthesis_NN ,_, and_CC syncytium_NN formation_NN ,_, as_IN described_VBN
          under_IN Materials_NNPS and_CC Methods_NNP ._. Yield_NNP of_IN progeny_NN virus_NN in_IN 20_CD
          nM_NN dsRNA-treated_JJ cells_NNS was_VBD found_VBN to_TO be_VB reduced_VBN by_IN 10_CD
          fold_VB ,_, and_CC was_VBD reduced_VBN by_IN at_IN least_JJS 10_CD 4_CD fold_VB at_IN 100_CD and_CC 300_CD
          nM_NN dsRNA_NN (_( data_NNS not_RB shown_VBN )_) ._. 
          De_NNP novo_NN viral_JJ protein_NN synthesis_NN was_VBD
          measured_VBN by_IN metabolic_JJ labeling_VBG with_IN S_NNP 35_CD -_: Met_NNP /_NN Cys_NNP followed_VBN
          by_IN immunoprecipitation_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 1_LS ,_, all_DT viral_JJ
          proteins_NNS detectable_JJ in_IN the_DT precipitate_NN were_VBD drastically_RB
          diminished_VBN in_IN the_DT dsRNA-treated_JJ cells_NNS ,_, as_IN would_MD be_VB
          expected_VBN in_IN the_DT event_NN of_IN a_DT loss_NN of_IN the_DT P_NN protein_NN ._. The_DT
          inhibition_NN of_IN viral_JJ growth_NN was_VBD further_RBR reflected_VBD in_IN the_DT
          essentially_RB complete_JJ loss_NN of_IN cell_NN fusion_NN (_( syncytia_NN )_) in_IN
          the_DT treated_VBN cells_NNS (_( Fig_NNP ._. 2_LS )_) ._. In_IN fact_NN ,_, the_DT RSV-infected_NNP
          anti-_NN P_NN dsRNA-treated_JJ cells_NNS were_VBD morphologically_RB
          indistinguishable_JJ from_IN control_NN uninfected_JJ ones_NNS even_RB at_IN 5_CD
          days_NNS post-infection_JJ ,_, which_WDT was_VBD the_DT longest_JJS time_NN period_NN
          for_IN which_WDT they_PRP were_VBD observed_VBN ._. The_DT presence_NN of_IN equal_JJ
          amounts_NNS of_IN actin_NN in_IN all_PDT the_DT samples_NNS confirmed_VBD that_IN the_DT
          observed_VBN inhibition_NN of_IN viral_JJ proteins_NNS is_VBZ not_RB due_JJ to_TO a_DT
          general_JJ degradation_NN of_IN proteins_NNS ._.
          The_DT specificity_NN of_IN dsRNA_NN activity_NN was_VBD further_RBR tested_VBN
          by_IN using_VBG a_DT dsRNA_NN against_IN cellular_JJ lamin_NN A_DT /_NN C_NNP that_WDT was_VBD
          earlier_RBR shown_VBN to_TO specifically_RB abrogate_NN lamin_NN A_DT /_NN C_NNP
          synthesis_NN in_IN a_DT variety_NN of_IN cultured_JJ cell_NN lines_NNS [_NN 2_CD ]_NN ._. As_IN
          shown_VBN in_IN Fig_NNP ._. 1_LS (_( lane_NN '_'' La_NNP '_POS )_) ,_, the_DT anti-lamin_JJ dsRNA_NN ,_, while_IN
          abrogating_VBG lamin_NN protein_NN (_( data_NNS not_RB shown_VBN )_) had_VBD no_DT effect_NN
          on_IN RSV_NNP protein_NN synthesis_NN ._. Furthermore_RB ,_, a_DT mismatched_JJ
          anti-_NN P_NN dsRNA_NN in_IN which_WDT the_DT lowercase_NN A-U_NNP base_NN pair_NN (_( see_VB
          the_DT dsRNA_NN sequences_NNS in_IN Materials_NNPS and_CC Methods_NNP )_) was_VBD altered_VBN
          to_TO a_DT G-C_NNP pair_NN also_RB failed_VBD to_TO inhibit_VB viral_JJ translation_NN
          (_( data_NNS not_RB shown_VBN )_) ,_, confirming_VBG that_IN a_DT perfect_JJ match_NN is_VBZ
          needed_VBN for_IN the_DT dsRNA_NN effect_NN ,_, hence_RB its_PRP$ extreme_JJ
          specificity_NN of_IN action_NN ._.
        
        
          Lack_NN of_IN syncytium_NN in_IN RSV-infected_NNP cells_NNS treated_VBN
          with_IN anti-_NN F_NN dsRNA_NN
          Fusion_NNP of_IN the_DT infected_JJ cells_NNS is_VBZ a_DT hallmark_NN of_IN all_DT
          Paramyxoviruses_NNP including_VBG RSV_NNP (_( as_RB also_RB in_IN some_DT other_JJ
          viruses_NNS ,_, such_JJ as_IN HIV_NNP )_) ,_, and_CC the_DT resultant_JJ mass_NN of_IN fused_JJ
          cells_NNS is_VBZ referred_VBN as_IN a_DT syncytium_NN ,_, from_IN which_WDT respiratory_JJ
          syncytial_NN virus_NN derives_VBZ its_PRP$ middle_JJ name_NN ._. The_DT fusion_NN
          protein_NN F_NN is_VBZ by_IN far_RB the_DT most_RBS important_JJ viral_JJ glycoprotein_NN
          that_WDT is_VBZ central_JJ to_TO the_DT cell_NN fusion_NN activity_NN [_NN 29_CD ]_NN ._.
          Since_IN the_DT P_NN and_CC F_NN proteins_NNS have_VBP such_JJ diverse_JJ roles_NNS in_IN
          viral_JJ life_NN cycle_NN ,_, we_PRP decided_VBD to_TO investigate_VB the_DT effect_NN of_IN
          dsRNA_NN on_IN F_NN as_IN a_DT second_JJ test_NN gene_NN ,_, and_CC also_RB to_TO compare_VB and_CC
          contrast_VB the_DT two_CD respective_JJ phenotypes_NNS ._.
          First_LS ,_, to_TO test_VB the_DT effectiveness_NN of_IN the_DT anti-_NN F_NN dsRNA_NN
          intracellularly_RB ,_, we_PRP probed_JJ the_DT infected_JJ cell_NN monolayer_NN
          with_IN anti-_NN F_NN antibody_NN by_IN indirect_JJ immunofluorescence_NN (_( Fig_NNP ._.
          3_LS )_) ._. Results_NNS clearly_RB demonstrated_VBD the_DT abundant_JJ synthesis_NN
          of_IN F_NN protein_NN as_IN cytoplasmic_JJ fluorescence_NN in_IN cells_NNS that_WDT
          were_VBD not_RB treated_VBN with_IN dsRNA_NN ;_: the_DT nuclei_NN of_IN the_DT same_JJ cells_NNS
          could_MD be_VB visualized_JJ by_IN staining_VBG with_IN DAPI_NNP ._. In_IN contrast_NN ,_,
          cells_NNS treated_VBN with_IN just_RB 3_CD nM_NN anti-_NN F_NN dsRNA_NN showed_VBD a_DT
          substantial_JJ loss_NN of_IN F_NN stain_VB ._. At_IN 20_CD nM_NN dsRNA_NN ,_, F_NN protein_NN
          was_VBD undetectable_JJ ._.
          Second_JJ ,_, immunoblot_NN analysis_NN (_( Fig_NNP ._. 4_LS ,_, top_JJ panel_NN )_)
          revealed_VBD that_DT anti-_NN F_NN dsRNA_NN ,_, at_IN concentrations_NNS as_RB low_JJ as_IN
          20_CD nM_NN ,_, produced_VBD a_DT severe_JJ reduction_NN in_IN F_NN protein_NN levels_NNS ._.
          Again_RB ,_, no_DT effect_NN was_VBD seen_VBN on_IN cellular_JJ profilin_NN ,_, ruling_NN
          out_RP a_DT general_JJ protein_NN loss_NN ._. The_DT anti-_NN F_NN dsRNA_NN also_RB had_VBD no_DT
          effect_NN on_IN P_NN protein_NN levels_NNS ,_, suggesting_VBG that_IN such_JJ dsRNAs_NNS
          do_VBP not_RB activate_VBP a_DT general_JJ antiviral_JJ response_NN that_WDT might_MD
          abrogate_NN all_DT viral_JJ mRNA_NN translation_NN ._. This_DT was_VBD further_JJ
          corroborated_JJ by_IN the_DT direct_JJ measurement_NN of_IN 
          de_IN novo_NN viral_JJ protein_NN synthesis_NN by_IN
          metabolic_JJ labeling_VBG (_( Fig_NNP ._. 4_LS ,_, bottom_JJ panel_NN )_) ._. Results_NNS showed_VBD
          that_IN the_DT synthesis_NN of_IN F_NN only_RB was_VBD affected_VBN while_IN all_DT other_JJ
          viral_JJ proteins_NNS were_VBD translated_VBN in_IN normal_JJ amounts_NNS ,_, which_WDT
          is_VBZ in_IN agreement_NN with_IN the_DT notion_NN that_DT F_NN has_VBZ little_JJ or_CC no_DT
          role_NN in_IN intracellular_NN viral_JJ macromolecular_NN synthesis_NN ._.
          Finally_RB ,_, the_DT phenotype_NN of_IN F_NN protein_NN loss_NN was_VBD tested_VBN by_IN
          examining_VBG syncytia_NN formation_NN ,_, and_CC as_IN presented_VBN in_IN Fig_NNP ._. 2_LS ,_,
          no_DT syncytia_NN could_MD be_VB discerned_JJ in_IN anti-_NN F_NN dsRNA-treated_JJ
          cells_NNS (_( Panel_NNP B_NNP )_) ._. However_RB ,_, a_DT cytopathic_JJ effect_NN was_VBD still_RB
          visible_JJ ,_, which_WDT is_VBZ most_RBS likely_JJ the_DT result_NN of_IN intracellular_NN
          replication_NN of_IN the_DT virus_NN ._. This_DT demonstrates_VBZ an_DT
          interesting_JJ contrast_NN with_IN the_DT anti-_NN P_NN dsRNA_NN (_( Panel_NNP C_NNP )_) ,_,
          which_WDT inhibited_VBD all_DT viral_JJ gene_NN expression_NN ,_, and_CC therefore_RB ,_,
          the_DT resultant_JJ monolayer_NN exhibited_VBN essentially_RB the_DT same_JJ
          appearance_NN as_IN the_DT uninfected_JJ one_CD (_( Panel_NNP D_NNP )_) ._.
          Direct_JJ measurement_NN of_IN intracellular_NN F_NN mRNA_NN by_IN
          semi-quantitative_JJ RT-PCR_NNP showed_VBD a_DT nearly_RB 15_CD -_: fold_VB loss_NN
          caused_VBN by_IN anti-_NN F_NN dsRNA_NN (_( Fig_NNP ._. 5_LS ,_, top_JJ panel_NN )_) ._. Similar_JJ
          RT-PCR_NNP of_IN viral_JJ genomic_JJ RNA_NNP ,_, viral_JJ P_NN mRNA_NN ,_, or_CC cellular_JJ
          actin_NN mRNA_NN revealed_VBD essentially_RB no_DT reduction_NN ,_, suggesting_VBG
          that_IN the_DT dsRNA_NN did_VBD not_RB activate_VBP a_DT general_JJ antiviral_JJ
          response_NN ,_, and_CC did_VBD not_RB directly_RB target_VB genomic_JJ RNA_NNP ._.
          Together_RB ,_, these_DT results_NNS directly_RB demonstrate_VBP that_IN the_DT
          dsRNAs_NNS promote_VBP ablation_NN of_IN the_DT specific_JJ mRNA_NN target_NN ,_,
          which_WDT most_RBS likely_JJ underlies_NNS the_DT loss_NN of_IN the_DT respective_JJ
          proteins_NNS ._.
        
        
          Anti-_NNP RSV_NNP dsRNAs_NNS do_VBP not_RB activate_VBP an_DT interferon_NN
          response_NN
          As_IN mentioned_VBN before_RB ,_, cytoplasmic_JJ dsRNA_NN can_MD trigger_VB a_DT
          series_NN of_IN signaling_VBG reactions_NNS that_WDT lead_VBP to_TO interferon_NN
          (_( IFN_NNP )_) synthesis_NN [_NN 5_CD 6_CD ]_NN ._. In_IN the_DT "_'' interferon_NN response_NN "_'' ,_,
          dsRNA_NN molecules_NNS activate_VBP protein_NN kinase_NN PKR_NNP and_CC
          2_CD '_POS ,_, 5_CD '_POS -_: oligonucleotide_NN synthetase_NN ._. One_CD of_IN the_DT effects_NNS of_IN
          PKR_NNP is_VBZ to_TO phosphorylate_NN the_DT α_NN subunit_NN of_IN the_DT general_JJ
          translation_NN initiation_NN factor_NN eIF-_NN 2_CD ,_, which_WDT constitutes_VBZ a_DT
          major_JJ mechanism_NN for_IN global_JJ translation_NN arrest_NN ._. The_DT 2_CD '_POS ,_,
          5_CD '_POS -_: oligonucleotide_NN synthetase_NN activates_NNS RNase_NNP L_NNP that_IN in_IN
          turn_NN catalyses_NNS non-specific_JJ degradation_NN of_IN mRNA_NN ._. Since_IN
          NNR_NNP viruses_NNS co-opt_JJ the_DT cellular_JJ translation_NN machinery_NN ,_,
          the_DT interferon_NN response_NN thus_RB causes_VBZ severe_JJ inhibition_NN of_IN
          viral_JJ translation_NN ._. Interestingly_RB ,_, the_DT IFN_NNP response_NN
          requires_VBZ long_JJ dsRNA_NN [_NN 5_CD 6_CD ]_NN ,_, and_CC it_PRP has_VBZ been_VBN conjectured_JJ
          that_IN the_DT improved_VBN specificity_NN of_IN the_DT 21_CD -_: nucleotide_NN long_JJ
          dsRNA_NN in_IN cultured_JJ mammalian_JJ cells_NNS is_VBZ probably_RB due_JJ to_TO
          their_PRP$ inability_NN to_TO activate_VBP the_DT IFN_NNP response_NN [_NN 2_CD ]_NN ._. We_PRP
          provide_VBP several_JJ lines_NNS of_IN direct_JJ and_CC indirect_JJ evidence_NN
          that_IN the_DT dsRNAs_NNS described_VBD here_RB did_VBD not_RB activate_VBP a_DT general_JJ
          IFN_NNP response_NN ._. First_LS ,_, the_DT inhibitory_NN effect_NN of_IN each_DT dsRNA_NN
          was_VBD gene-specific_JJ (_( Figs_NNP ._. 1_LS ,_, 2_CD ,_, 4_LS )_) ._. Second_JJ ,_, growth_NN of_IN VSV_NNP
          is_VBZ known_VBN to_TO be_VB highly_RB sensitive_JJ to_TO IFN_NNP ,_, however_RB ,_, its_PRP$
          replication_NN in_IN A_DT 549_CD cells_NNS was_VBD not_RB affected_VBN by_IN any_DT of_IN the_DT
          dsRNAs_NNS described_VBD here_RB (_( data_NNS not_RB shown_VBN )_) ._. Lastly_NNP ,_, elevated_VBD
          phosphorylation_NN of_IN eIF-_NN 2_CD α_NN has_VBZ been_VBN used_VBN as_IN a_DT diagnostic_JJ
          marker_NN of_IN IFN_NNP response_NN [_NN 30_CD ]_NN ._. We_PRP ,_, therefore_RB ,_, examined_VBD
          the_DT phosphorylation_NN status_NN of_IN eIF-_NN 2_CD α_NN in_IN A_DT 549_CD cells_NNS
          following_VBG transfection_NN with_IN these_DT dsRNAs_NNS ._. Results_NNS (_( Fig_NNP ._.
          5_LS ,_, bottom_JJ panel_NN )_) showed_VBD no_DT increase_NN in_IN phosphorylation_NN ._.
          In_IN positive_JJ controls_NNS ,_, A_DT 549_CD cell_NN treated_VBN with_IN calcium_NN
          mobilizers_NNS (_( thapsigargin_NN or_CC A_DT 23178_CD )_) did_VBD increase_NN eIF-_NN 2_CD
          phosphorylation_NN ,_, as_IN has_VBZ been_VBN shown_VBN earlier_JJR [_NN 30_CD ]_NN ._. These_DT
          results_NNS provide_VBP the_DT first_JJ direct_JJ evidence_NN that_IN the_DT 21_CD -_: nt_RB
          long_JJ double-stranded_JJ siRNAs_NNS fail_VBP to_TO trigger_VB interferon_NN
          response_NN in_IN mammalian_JJ cells_NNS ,_, and_CC hence_RB ,_, can_MD be_VB used_VBN as_IN
          specific_JJ antiviral_JJ agents_NNS ._.
        
      
      
        Discussion_NNP
        In_IN this_DT communication_NN ,_, we_PRP establish_VB 21_CD -_: nucleotide_NN long_JJ
        double-stranded_JJ interfering_VBG RNA_NNP as_IN a_DT viable_JJ tool_NN to_TO ablate_NN
        specific_JJ cytoplasmic_JJ RNAs_NNP ,_, as_IN exemplified_VBN by_IN the_DT mRNAs_NNS of_IN a_DT
        RNA_NNP virus_NN ._. The_DT major_JJ findings_NNS are_VBP :_: (_( i_NNP )_) The_DT ablation_NN is_VBZ
        highly_RB efficient_JJ :_: nanomolar_NN concentrations_NNS of_IN dsRNA_NN can_MD
        lead_VB to_TO a_DT 10_CD -_: 20_CD fold_VB reduction_NN of_IN the_DT corresponding_JJ
        protein_NN ._. The_DT two_CD RSV_NNP mRNAs_NNS that_IN we_PRP have_VBP targeted_VBN here_RB ,_,
        namely_RB P_NN and_CC F_NN ,_, are_VBP relatively_RB abundant_JJ viral_JJ mRNAs_NNS ._. In_IN
        fact_NN ,_, they_PRP respectively_RB represent_VBP the_DT 4_CD thand_NN 5_CD thmost_NN
        abundant_JJ viral_JJ mRNAs_NNS in_IN the_DT infected_JJ cell_NN ._. Thus_RB ,_, we_PRP predict_VBP
        that_IN an_DT even_RB lower_JJR concentration_NN of_IN dsRNA_NN ,_, perhaps_RB in_IN the_DT
        sub-nanomolar_JJ range_NN ,_, might_MD be_VB able_JJ to_TO destroy_VB NNR_NNP viral_JJ
        mRNAs_NNS that_WDT are_VBP rarer_NN ,_, such_JJ as_IN those_DT of_IN RSV_NNP M_NNP 2_CD and_CC L_NNP
        proteins_NNS ._. This_DT is_VBZ currently_RB being_VBG tested_VBN ._. It_PRP is_VBZ to_TO be_VB noted_VBN
        that_IN a_DT chemical_NN is_VBZ generally_RB considered_VBN a_DT promising_JJ
        pharmaceutical_NN if_IN it_PRP is_VBZ effective_JJ at_IN sub-micromolar_JJ
        concentrations_NNS ,_, (_( ii_NN )_) The_DT effect_NN is_VBZ highly_RB specific_JJ :_: dsRNA_NN
        against_IN one_CD viral_JJ mRNA_NN did_VBD not_RB affect_VB other_JJ viral_JJ mRNAs_NNS or_CC
        the_DT cellular_JJ genes_NNS tested_VBN here_RB ._. In_IN this_DT regard_NN ,_, dsRNA_NN
        generally_RB surpasses_NNS the_DT standard_JJ antisense_NN technology_NN based_VBN
        on_IN oligodeoxynucleotides_NNS (_( ODNs_NNP )_) ,_, whose_WP$ specificity_NN has_VBZ
        often_RB been_VBN debated_VBN ._. Moreover_RB ,_, since_IN the_DT most_RBS potent_JJ
        antisense_NN ODNs_NNP rely_VB on_IN the_DT degradation_NN of_IN target_NN RNA_NNP by_IN
        RNase_NNP H_NNP [_NN 31_CD ]_NN ,_, which_WDT is_VBZ a_DT predominantly_RB nuclear_JJ enzyme_NN ,_,
        this_DT mechanism_NN is_VBZ not_RB available_JJ to_TO RNA_NNP viruses_NNS that_WDT are_VBP
        strictly_RB cytoplasmic_JJ ._. (_( iii_NN )_) Lack_NN of_IN interferon_NN response_NN :_: We_PRP
        provide_VBP direct_JJ experimental_JJ evidence_NN that_IN the_DT 21_CD -_: nt_RB dsRNA_NN
        does_VBZ not_RB trigger_VB an_DT IFN_NNP response_NN ,_, which_WDT is_VBZ an_DT advantage_NN
        because_IN an_DT IFN_NNP response_NN would_MD have_VB caused_VBN a_DT general_JJ and_CC
        non-specific_JJ inhibition_NN of_IN all_DT cap-dependent_JJ translation_NN [_NN
        5_CD ]_NN ._. (_( iv_NN )_) Regulation_NNP any_DT time_NN :_: Although_IN we_PRP have_VBP not_RB tested_VBN
        this_DT specifically_RB ,_, one_PRP can_MD ,_, in_IN principle_NN ,_, transfect_NN the_DT
        virus-infected_JJ cell_NN with_IN dsRNA_NN at_IN any_DT time_NN point_NN during_IN
        infection_NN ._. This_DT will_MD allow_VB ablation_NN of_IN a_DT specific_JJ protein_NN
        at_IN different_JJ times_NNS in_IN infection_NN and_CC allow_VB one_CD to_TO determine_VB
        if_IN the_DT same_JJ "_'' mutation_NN "_'' may_MD have_VB early_JJ and_CC late_JJ phenotypes_NNS ._.
        In_IN addition_NN ,_, this_DT will_MD allow_VB mutational_NN analysis_NN of_IN
        essential_JJ genes_NNS ,_, genetic_JJ deletion_NN of_IN which_WDT may_MD result_VB in_IN a_DT
        nonviable_JJ virus_NN ._. In_IN this_DT regard_NN ,_, the_DT dsRNA_NN technique_NN is_VBZ
        akin_JJ to_TO a_DT temperature-shift_JJ experiment_NN using_VBG a_DT
        temperature-sensitive_JJ mutant_JJ virus_NN ,_, however_RB ,_, as_IN implied_VBN
        earlier_RBR ,_, conditional_JJ lethal_JJ mutations_NNS are_VBP not_RB available_JJ for_IN
        the_DT vast_JJ majority_NN of_IN viral_JJ genes_NNS ._. (_( v_NN )_) Ease_NNP of_IN use_NN :_: The_DT
        dsRNA_NN approach_NN is_VBZ relatively_RB simple_JJ to_TO design_VB ,_, and_CC its_PRP$
        application_NN in_IN cell_NN culture_NN only_RB requires_VBZ the_DT standard_JJ
        transfection_NN technology_NN that_WDT already_RB exists_VBZ ._. (_( vi_NN )_) Multiple_NNP
        targets_NNS :_: It_PRP is_VBZ also_RB possible_JJ to_TO deplete_VB multiple_JJ cellular_JJ
        or_CC viral_JJ gene_NN mRNAs_NNS in_IN any_DT combination_NN ,_, either_CC
        simultaneously_RB or_CC in_IN a_DT temporal_JJ order_NN ,_, and_CC thus_RB ask_VB
        questions_NNS about_IN the_DT interaction_NN between_IN the_DT phenotypes_NNS ._.
        (_( vii_NN )_) Normal_NNP infection_NN environment_NN :_: As_IN we_PRP have_VBP contended_VBN ,_, a_DT
        major_JJ benefit_NN of_IN this_DT approach_NN in_IN viral_JJ reverse_NN genetics_NNS is_VBZ
        that_IN one_PRP can_MD start_VB with_IN standard_JJ wild_JJ type_NN virus_NN (_( or_CC even_RB a_DT
        relatively_RB uncharacterized_JJ field_NN isolate_VB )_) with_IN no_DT
        requirements_NNS of_IN recombinant_JJ expression_NN ,_, and_CC thus_RB ,_, the_DT
        cellular_JJ milieu_NN is_VBZ only_RB minimally_RB perturbed_VBD ,_, if_IN at_IN all_DT ._.
        Lastly_NNP ,_, the_DT lack_NN of_IN effect_NN of_IN the_DT anti-_NN F_NN dsRNA_NN on_IN viral_JJ
        genome_NN replication_NN deserves_VBZ special_JJ attention_NN ._. As_IN described_VBD
        earlier_RBR (_( in_IN the_DT beginning_NN of_IN the_DT Results_NNS section_NN )_) ,_,
        intracellular_NN NNR_NNP viral_JJ replication_NN generates_VBZ both_DT
        negative-_NN and_CC positive-strand_JJ full-length_JJ genomic_JJ RNA_NNP ,_, each_DT
        of_IN which_WDT should_MD find_VB complementarity_NN to_TO the_DT appropriate_JJ
        strand_NN of_IN the_DT anti-_NN F_NN dsRNA_NN ._. In_IN general_JJ ,_, genome-length_JJ RNAs_NNP
        of_IN both_DT positive_JJ and_CC negative_JJ sense_NN could_MD ,_, therefore_RB ,_, be_VB
        potential_JJ targets_NNS for_IN RNA_NNP interference_NN ,_, resulting_VBG in_IN severe_JJ
        inhibition_NN of_IN replication_NN ._. We_PRP speculate_VBP that_IN the_DT genomic_JJ
        and_CC antigenomic_JJ RNA_NNP of_IN NNR_NNP viruses_NNS escape_VB the_DT onslaught_NN of_IN
        dsRNA_NN because_IN they_PRP are_VBP tightly_RB wrapped_VBN with_IN the_DT
        nucleocapsid_NN protein_NN N_NNP ,_, which_WDT makes_VBZ them_PRP inaccessible_JJ to_TO
        the_DT dsRNA_NN and_CC /_NN or_CC the_DT RNAi_NNP silencing_VBG complex_JJ (_( RISC_NNP )_) ._. As_IN
        mentioned_VBN before_RB ,_, the_DT N-_NNP encapsidated_JJ genome-length_JJ RNAs_NNP are_VBP
        indeed_RB extremely_RB resistant_JJ to_TO nucleases_NNS ,_, to_TO the_DT extent_NN that_DT
        formation_NN of_IN such_JJ nuclease-resistant_JJ RNA_NNP products_NNS is_VBZ in_IN
        fact_NN considered_VBD a_DT defining_VBG criterion_NN for_IN viral_JJ replication_NN 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN [_NN 32_CD ]_NN ._. While_IN the_DT resistance_NN
        of_IN the_DT viral_JJ genomic_JJ RNA_NNP to_TO dsRNA_NN has_VBZ important_JJ
        ramifications_NNS for_IN antiviral_JJ therapy_NN ,_, it_PRP is_VBZ also_RB clear_JJ that_IN
        the_DT dsRNA_NN approach_NN cannot_NN be_VB used_VBN against_IN 
        cis_NNS -_: acting_VBG NNR_NNP viral_JJ genomic_JJ
        sequences_NNS such_JJ as_IN the_DT intergenic_JJ regions_NNS ,_, for_IN which_WDT the_DT
        cDNA-based_JJ approach_NN will_MD continue_VB to_TO be_VB the_DT method_NN of_IN
        choice_NN [_NN 16_CD ]_NN ._. It_PRP is_VBZ obvious_JJ that_IN a_DT creative_JJ combination_NN
        of_IN the_DT two_CD techniques_NNS will_MD lead_VB to_TO exciting_JJ possibilities_NNS
        in_IN the_DT reverse_NN genetics_NNS of_IN RNA_NNP viruses_NNS and_CC in_IN the_DT antiviral_JJ
        regimen_NN ._.
      
      
        Conclusions_NNP
        Properly_NNP designed_VBD synthetic_JJ 21_CD -_: nucleotide_NN long_JJ
        double-stranded_JJ RNA_NNP (_( dsRNA_NN )_) molecules_NNS can_MD effectively_RB and_CC
        specifically_RB abrogate_NN translation_NN of_IN target_NN RNAs_NNP without_IN
        activating_VBG a_DT general_JJ interferon_NN response_NN ._. When_WRB applied_VBN
        against_IN mRNAs_NNS of_IN cytoplasmic_JJ RNA_NNP viruses_NNS ,_, the_DT dsRNAs_NNS caused_VBD
        degradation_NN of_IN the_DT specific_JJ viral_JJ mRNA_NN and_CC resultant_JJ
        ablation_NN of_IN the_DT specific_JJ viral_JJ protein_NN ._. The_DT technique_NN is_VBZ
        quick_JJ ,_, simple_JJ ,_, and_CC can_MD be_VB used_VBN against_IN wild_JJ type_NN RNA_NNP
        viruses_NNS in_IN standard_JJ tissue_NN culture_NN at_IN any_DT point_NN in_IN the_DT
        infection_NN cycle_NN ._. Post-transcriptional_NNP gene_NN silencing_VBG by_IN
        such_JJ dsRNA_NN molecules_NNS should_MD facilitate_VB the_DT reverse_NN genetics_NNS
        and_CC functional_JJ genomics_NNS of_IN RNA_NNP genomes_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Double-stranded_NNP RNA_NNP
          The_DT following_VBG dsRNA_NN sequences_NNS with_IN 3_CD '_POS -_: dT_NN extensions_NNS
          were_VBD synthesized_JJ against_IN RSV_NNP P_NN ,_, RSV_NNP F_NNP ,_, and_CC cellular_JJ lamin_NN
          A_DT /_NN C_NNP mRNA_NN sequences_NNS (_( Accession_NNP numbers_NNS Ml_NNP 1486_CD ,_, M_NNP 22643_CD ,_, and_CC
          X_NNP 03444_CD ,_, respectively_RB )_) ,_, following_VBG the_DT design_NN
          recommendations_NNS of_IN Tuschl_NNP and_CC coworkers_NNS [_NN 2_CD ]_NN :_:
          P_NN :_: 5_CD '_POS CGAUAAUAUaACUGCAAGATT_NNP 3_CD '_''
          3_LS '_POS TTGCUAUUAUAuUGACGUUCU_NNP 5_CD '_''
          F_NN :_: 5_CD '_POS UGCUGUAACAGAAUUGCAGTT_NNP 3_CD '_''
          3_LS '_POS TTACGACAUUGUCUUAACGUC_NNP 5_CD '_''
          Lamin_NNP :_: 5_CD '_POS CUGGACUUCCAGAAGAACATT_NNP 3_CD '_''
          3_LS '_POS TTGACCUGAAGGUCUUCUUGU_NNP 5_CD '_''
          The_DT two_CD T_NN 's_POS at_IN the_DT 3_CD '_POS -_: end_NN of_IN all_DT RNAs_NNP were_VBD
          2_CD '_POS -_: deoxythymidines_NNS ._. The_DT dT_NN residues_NNS most_RBS likely_RB provided_VBN
          stability_NN against_IN RNases_NNP [_NN 2_CD ]_NN ,_, since_IN they_PRP produced_VBD a_DT
          more_RBR reproducible_JJ and_CC sustained_VBN effect_NN at_IN a_DT substantially_RB
          lower_JJR concentration_NN ,_, compared_VBN to_TO RNAs_NNP that_WDT contained_VBD all_DT
          ribonucleotides_NNS but_CC an_DT otherwise_RB identical_JJ sequence_NN (_( data_NNS
          not_RB shown_VBN )_) ._. All_DT oligonucleotide_NN were_VBD synthesized_JJ by_IN
          Dharmacon_NNP Research_NNP (_( Lafayette_NNP ,_, CO_NNP )_) using_VBG their_PRP$
          recommended_JJ 2_CD '_POS -_: ACE_NNP protection_NN chemistry_NN ,_, and_CC then_RB
          gel-purified_JJ ._. Deprotection_NNP of_IN the_DT RNA_NNP and_CC hybridization_NN
          of_IN the_DT two_CD strands_NNS were_VBD carried_VBN out_IN according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN ._. In_IN the_DT mutant_JJ dsRNA_NN (_( for_IN P_NN )_) ,_, the_DT
          lowercase_NN a-u_JJ base_NN pair_NN was_VBD changed_VBN to_TO g-c_JJ (_( see_VB
          Results_NNS )_) ._.
        
        
          Transfection_NNP with_IN dsRNA_NN and_CC RSV_NNP infection_NN
          The_DT dsRNAs_NNS were_VBD introduced_VBN in_IN cells_NNS essentially_RB as_IN
          described_VBN [_NN 2_CD ]_NN ._. Briefly_NNP ,_, A_DT 549_CD cells_NNS were_VBD propagated_JJ in_IN
          standard_JJ MEM_NNP (_( Life_NNP Technologies_NNPS )_) supplemented_JJ with_IN 10_CD %_NN
          fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) and_CC penicillin-streptomycin_JJ ._.
          Twenty-four_CD h_NN before_IN transfection_NN ,_, cells_NNS were_VBD trypsinized_JJ
          and_CC transferred_VBN to_TO 12_CD -_: well_RB plates_NNS ._. Transfection_NNP with_IN
          dsRNAs_NNS was_VBD carried_VBN out_IN with_IN OligofectAMINE_NNP Reagent_NNP (_( Life_NNP
          Technologies_NNPS )_) in_IN OPTIMEM_NNP I_PRP (_( Life_NNP Technologies_NNPS )_) as_IN
          described_VBN by_IN the_DT manufacturer_NN for_IN adherent_NN cell_NN lines_NNS ._.
          Indicated_NNP amounts_NNS of_IN dsRNA_NN ,_, formulated_VBN into_IN liposomes_NNS ,_,
          were_VBD applied_VBN per_IN well_RB ,_, and_CC the_DT final_JJ volume_NN was_VBD 500_CD μl_NN
          per_IN well_RB ._. Cells_NNP were_VBD incubated_JJ for_IN 6_CD h_NN after_IN
          transfection_NN ,_, and_CC then_RB infected_VBN with_IN RSV_NNP Long_NNP strain_NN at_IN
          an_DT m_NN ._. o_NN ._. i_NNP ._. of_IN 4_CD [_NN 17_CD 33_CD ]_NN ,_, and_CC FBS_NNP was_VBD added_VBN back_RB to_TO 1_CD %_NN
          to_TO supplement_VB the_DT growth_NN of_IN the_DT virus_NN ._. A_DT second_JJ
          transfection_NN was_VBD performed_VBN after_IN 5_CD h_NN of_IN infection_NN and_CC FBS_NNP
          was_VBD again_RB restored_VBN to_TO 1_CD %_NN in_IN 12_CD h_NN after_IN second_JJ
          transfection_NN ._. At_IN 40_CD to_TO 48_CD h_NN after_IN the_DT first_JJ transfection_NN ,_,
          cells_NNS were_VBD photographed_VBN ,_, or_CC processed_VBD for_IN immunostaining_VBG
          (_( see_VB below_IN )_) ,_, RNA_NNP isolation_NN ,_, or_CC immunoblot_NN ,_, as_IN and_CC where_WRB
          indicated_VBD ._.
        
        
          Indirect_JJ immunofluorescence_NN
          Rabbit_NNP anti-_NN F_NN antibody_NN was_VBD raised_VBN against_IN a_DT synthetic_JJ
          peptide_NN ,_, and_CC was_VBD a_DT kind_NN gift_NN from_IN Dr_NNP ._. James_NNP E_NNP ._. Crowe_NNP ,_, Jr_NNP ._.
          (_( Vanderbilt_NNP University_NNP ,_, TN_NNP )_) ._. Rabbit_NNP polyclonal_NN antibody_NN
          against_IN RSV-P_NNP protein_NN has_VBZ been_VBN described_VBN [_NN 21_CD ]_NN ._.
          Indirect_JJ immunofluorescence_NN and_CC nuclear_JJ staining_VBG with_IN
          DAPI_NNP was_VBD performed_VBN essentially_RB as_IN described_VBN previously_RB [_NN
          33_CD ]_NN ._. A_DT 549_CD cells_NNS in_IN monolayer_NN ,_, grown_VBN on_IN cover_NN slips_VBZ ,_,
          were_VBD washed_VBN in_IN PBS_NNP and_CC fixed_VBN in_IN ice-cold_JJ 10_CD %_NN
          trichloracetic_JJ acid_NN for_IN 15_CD min_NN ,_, followed_VBN by_IN successive_JJ
          washes_NNS in_IN cold_JJ 70_CD %_NN ,_, 90_CD %_NN and_CC absolute_JJ ethanol_NN for_IN 3_CD min_NN
          each_DT ._. After_IN one_CD more_JJR PBS_NNP washing_VBG ,_, the_DT fixed_VBN cells_NNS were_VBD
          incubated_JJ for_IN 45_CD min_NN at_IN room_NN temperature_NN with_IN anti-_NN P_NN or_CC
          anti-_NN F_NN protein_NN antibody_NN in_IN PBS_NNP ._. Thereafter_RB ,_, cells_NNS were_VBD
          washed_VBN three_CD times_NNS for_IN 5_CD min_NN in_IN PBS_NNP and_CC incubated_JJ for_IN 45_CD
          min_NN at_IN room_NN temperature_NN with_IN TRITC-_NNP or_CC FITC-conjugated_NNP
          anti-rabbit_JJ IgG_NNP secondary_JJ antibody_NN (_( Sigma_NNP )_) diluted_VBN 1_CD :_: 75_CD ._.
          Nonspecific_NNP binding_JJ was_VBD eliminated_VBN by_IN three_CD washes_NNS in_IN
          PBS_NNP ._. Where_WRB mentioned_VBN ,_, nuclei_NN were_VBD stained_JJ with_IN DAPI_NNP
          (_( Sigma_NNP )_) after_IN the_DT final_JJ PBS_NNP wash_VB ._. Cells_NNP were_VBD visualized_JJ
          and_CC the_DT images_NNS digitally_RB captured_VBN in_IN an_DT Olympus_NNP BMAX_NNP
          Epifluorescence_NNP microscope_NN using_VBG a_DT 100_CD ×_NN oil-immersion_JJ
          objective_NN and_CC appropriate_JJ filters_NNS [_NN 12_CD 33_CD ]_NN ._.
        
        
          Ex_NNP vivophosphorylation_NN assay_NN
          Metabolic_NNP labeling_VBG of_IN cells_NNS and_CC immunoprecipitation_NN
          was_VBD performed_VBN essentially_RB as_IN described_VBN previously_RB [_NN 21_CD 30_CD
          ]_NN ._. In_IN brief_JJ ,_, confluent_NN monolayers_NNS of_IN A_DT 549_CD cells_NNS were_VBD
          transfected_JJ with_IN appropriate_JJ dsRNA_NN (_( at_IN 20_CD nM_NN final_JJ )_) as_IN
          described_VBN above_IN ,_, and_CC at_IN 8_CD hr_NN post-transfection_JJ ,_, were_VBD
          washed_VBN with_IN a_DT phosphate-free_JJ buffer_NN (_( 120_CD mM_NN NaCl_NNP ,_, 5_CD mM_NN
          KCl_NNP ,_, 1_CD ._. 5_CD mM_NN MgCl_NNP 
          2_CD ,_, 0_CD ._. 25_CD mM_NN CaCl_NNP 
          2_CD ,_, 25_CD mM_NN NaHCO_NNP 
          3_CD ,_, 20_CD mM_NN HEPES_NNP [_NN pH_NN 7_CD ._. 4_CD ]_NN )_) and_CC labeled_VBN
          with_IN 32_CD P-_NNP orthophosphate_NN (_( 500_CD μCi_NN /_NN ml_NN )_) (_( Amersham_NNP )_) in_IN
          Dulbecco-modified_NNP Eagle_NNP MEM_NNP lacking_VBG both_DT phosphate_NN and_CC
          pyruvate_NN ._. Where_WRB mentioned_VBN ,_, thapsigargin_NN or_CC A_DT 23178_CD was_VBD
          used_VBN at_IN final_JJ concentrations_NNS of_IN 100_CD nM_NN ,_, and_CC was_VBD added_VBN to_TO
          the_DT cells_NNS 15_CD min_NN before_IN addition_NN of_IN the_DT 32_CD P-_NNP containing_VBG
          medium_NN containing_VBG the_DT same_JJ concentration_NN of_IN the_DT drugs_NNS ._.
          After_IN a_DT 1_CD h_NN labeling_VBG period_NN ,_, all_DT cells_NNS were_VBD washed_VBN with_IN
          phosphate-buffered_JJ saline_NN without_IN Ca_MD 2_CD +_NN and_CC Mg_NNP 2_CD +_NN and_CC
          disrupted_VBN as_IN described_VBN previously_RB to_TO obtain_VB the_DT total_JJ
          lysate_NN ._. The_DT eIF-_NN 2_CD was_VBD precipitated_VBD with_IN a_DT polyclonal_NN
          antibody_NN against_IN human_JJ eIF-_NN 2_CD α_NN (_( C-_NNP 20_CD )_) (_( Santa_NNP Cruz_NNP Biotech_NNP )_)
          in_IN the_DT presence_NN of_IN protein_NN G-S_NNP epharose_NN (_( Amersham_NNP )_) for_IN 1_CD h_NN
          at_IN 10_CD °_NN C_NNP ,_, and_CC then_RB processed_VBN as_IN described_VBN previously_RB [_NN 21_CD
          ]_NN ._. The_DT immunoprecipitates_NNS were_VBD subjected_VBN to_TO SDS-PAGE_NNP
          followed_VBN by_IN autoradiography_NN to_TO examine_VB eIF-_NN 2_CD
          phosphorylation_NN ._.
          To_TO monitor_VB total_JJ eIF-_NN 2_CD α_NN in_IN the_DT cell_NN ,_, a_DT parallel_VB A_DT 549_CD
          monolayer_NN was_VBD treated_VBN identically_RB except_IN that_IN the_DT labeled_VBN
          orthophosphate_NN was_VBD omitted_VBN ._. Portions_NNP of_IN the_DT total_JJ cell_NN
          lysate_NN were_VBD analyzed_VBN by_IN SDS-PAGE_NNP followed_VBN by_IN immunoblot_NN
          with_IN anti-e_JJ IF-_NNP 2_CD α_NN antibody_NN ._. All_DT immunoblots_NNS (_( Western_JJ
          blots_NNS )_) were_VBD performed_VBN essentially_RB as_IN described_VBN [_NN 17_CD ]_NN ._.
          Thapsigargin_NNP and_CC A_DT 23178_CD were_VBD from_IN Sigma-_NNP Aldrich_NNP ._.
        
        
          Reverse_VBP transcription-_NN PCR_NNP (_( RT-PCR_NNP )_)
          Quantitation_NNP of_IN specific_JJ mRNAs_NNS by_IN RT-PCR_NNP was_VBD done_VBN
          essentially_RB as_IN described_VBN [_NN 34_CD ]_NN ._. Briefly_NNP ,_, total_JJ RNA_NNP was_VBD
          isolated_VBN from_IN trypsinized_JJ cell_NN monolayers_NNS using_VBG the_DT
          Quickprep_NNP Micro_NNP ™_NN mRNA_NN purification_NN kit_NN from_IN Pharmacia_NNP
          Biotech_NNP (_( Piscataway_NNP ,_, NJ_NNP )_) ._. Equal_NNP amounts_NNS of_IN total_JJ RNA_NNP were_VBD
          subjected_VBN to_TO reverse_VB transcription_NN using_VBG the_DT 
          C_NNP ._. therm_NN ._. RT_NNP system_NN (_( Roche_NNP
          Molecular_NNP Biochemicals_NNP ,_, Indianapolis_NNP ,_, IN_IN )_) at_IN 65_CD °_NN C_NNP for_IN 1_CD
          hr_NN in_IN the_DT presence_NN of_IN 5_CD units_NNS of_IN RNasin_NNP (_( Promega_NNP )_) ,_,
          followed_VBN by_IN PCR_NNP through_IN increasing_VBG number_NN of_IN cycles_NNS ._. The_DT
          primers_NNS were_VBD based_VBN on_IN RSV_NNP (_( 
          Acc_NNP #_# M_NNP 74568_CD )_) and_CC actin_NN (_( X_NNP 00351_CD )_)
          sequences_NNS ,_, and_CC are_VBP as_IN follows_VBZ (_( sense_NN and_CC antisense_NN ,_,
          respectively_RB )_) :_:
          P_NN :_: 5_CD '_POS CCCTTTTCTAAACTATACAAAGAAACC_NNP 3_CD '_POS and_CC
          5_CD '_POS AGCAGATGTAGGTCCTGCACTTG_NNP 3_CD '_'' ;_:
          F_NN :_: 5_CD '_POS AGTGTAATGGAACAGATGCCAAGG_NNP 3_CD '_POS and_CC
          5_CD '_POS GCAGGACCTTAGATACAGCAGTG_NNP 3_CD '_'' ;_:
          RSV_NNP genomic_JJ RNA_NNP :_: 5_CD '_POS AATGACCAATTATATGAATCAATTATCTG_NNP 3_CD '_POS and_CC
          5_CD '_POS GTTGACCAGGAATGTAAATGTGGC_NNP 3_CD '_'' ;_:
          β-actin_JJ :_: 5_CD '_POS CCTCACCCTGAAGTACCCCATC_NNP 3_CD '_POS and_CC
          5_CD '_POS GCCGTGGTGGTGAAGCTGTAGC_NNP 3_CD '_'' ._. The_DT RT-PCR_NNP products_NNS were_VBD
          198_CD ,_, 274_CD ,_, 307_CD ,_, and_CC 420_CD bp_NN long_JJ ,_, respectively_RB ,_, for_IN these_DT
          mRNAs_NNS ._. The_DT amount_NN of_IN RNA_NNP was_VBD optimized_JJ for_IN the_DT individual_JJ
          genes_NNS ,_, and_CC PCR_NNP samples_NNS were_VBD withdrawn_VBN at_IN 20_CD ,_, 22_CD ,_, 24_CD ,_, and_CC
          26_CD cycles_NNS of_IN amplification_NN and_CC analyzed_VBN by_IN standard_JJ
          agarose_NN gel_NN electrophoresis_NNS followed_VBN by_IN ethidium_NN bromide_NN
          staining_VBG ._.
        
      
    
  
